Andrographolides ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 13 | 多発性硬化症／視神経脊髄炎 | 1 |
13. 多発性硬化症／視神経脊髄炎
臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02273635 (ClinicalTrials.gov) | September 2014 | 3/10/2014 | Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS | Controlled, Randomized, Double-blind Clinical Trial, 24 Months Duration, to Compare the Efficacy, Safety and Tolerability of Andrographolide Versus Placebo in Patients With Progressive Forms of Multiple Sclerosis | Primary Progressive Multiple Sclerosis;Multiple Sclerosis, Secondary Progressive | Drug: Andrographolides;Drug: placebo | Innobioscience SpA | Pontificia Universidad Catolica de Chile;University of Chile;Universidad Austral de Chile | Recruiting | 18 Years | 70 Years | Both | 68 | Phase 1/Phase 2 | Chile |